Health and Healthcare
Vical $2 Million NIH Grant For Herpes Vaccine (VICL)
Published:
Vical, Incorporated (NASDAQ: VICL) has been awarded a $2 million Phase II small business technology transfer grant from the US National Institute of Allergy and Infectious Diseases department from the National Institues of Health.
The grant is to fund an ongoing development of Vical’s plasmid DNA vaccine against Herpes simplex virus type 2. This is none other than the sexually transmitted virus that causes genital herpes.
Research is being conducted at the University of Wasington and the University of Texas. The goal of the study is to be used in people who already have HSV-2 with a primary goal of reducing or eliminating periodic herpes viral flare-ups and the associated viral shedding and transmission.
The potential list of users could be tens of millions and there is currently no such vaccine or drug that is a true cure for this.
Vical’s market cap is a mere $146 million.
Jon C. Ogg
April 3, 2008
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.